Abstract 4801
Background
X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1) is a tumor suppressor that is frequently lost or down-regulated by aberrant promoter hypermethylation in multiple human cancers. To explore XAF1’s candidacy for a suppressor in breast tumorigenesis, we investigated its expression status in tumor cell lines and tissues, effect on ER regulation of cell growth, and the molecular basis for its function.
Methods
XAF1 expression was examined by RT-PCR, immunoblot and bisulfite sequencing. Molecular basis for the XAF1 interplay with ERa and BRCA1 was defined using gene transfection, siRNA-mediated depletion, immunoprecipitation, pull-down assays, ubiquitination assay, immunohistochemistry and animal studies.
Results
XAF1 expression was lost or abnormally diminished by promoter hypermethylation in a substantial fraction of cell lines and primary tumors. XAF1 expression shows an inverse correlation with ERα expression. In ERα-expressing cells, restoration of XAF1 expression extremely increased cellular sensitivity to estrogen-induced, ERα-mediated apoptosis. Likewise, in ERα-nonexpressing cells, recovery of ERα restoration led to the recovery of apoptotic response to estrogen in XAF1-dependent fashion. Intriguingly, XAF1 was found to directly bind to and destabilizes ERα and this interaction is crucial for its apoptosis-promoting activity. Mechanistically, XAF1 has the characteristic of binding with E3 ligase, XAF1 interacts with BRCA1 and subsequently stimulates BRCA1 binding to ERα and BRCA1-mediated K48 polyubiquitination of ERα. Using a series of truncated mutants, we determined the domains of XAF1, ERα, and BRCA1 that are required for the assembly formation. Additionally, XAF1 was characterized to be upregulated by estrogen at the transcription level through the p38, JNK, and NF-kB signaling pathway.
Conclusions
XAF1 is promoted by estrogen and its activation directs the apoptotic switch of estrogen function through the assembly of BRCA1-mediated ERα destruction complex. Our study illuminates the mechanistic consequence of epigenetic inactivation of XAF1 in human breast tumorigenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sung-Gil Chi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract